{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-032118","form_type":"8-K","ticker":"PALI","cik":"0001357459","company_name":"PALISADE BIO, INC.","filed_at":"2023-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.692227+00:00","generated_at":"2026-06-10T22:02:52.429175+00:00","sec_items":["1.01","2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Palisade Bio licenses Giiant Pharma's oral IBD drug candidates GT-2108 and GT-1908","bullets":["Exclusive worldwide license for Giiant's targeted prodrug platform; lead asset GT-2108 for ulcerative colitis.","IND/CTA filing for GT-2108 expected by Q3 2024; development supported by $500k Crohn's & Colitis Foundation grant.","Milestone payments (cash or stock at Palisade's election) and royalty payments on sales; Palisade to fund all costs after first IND/CTA approval.","Second program GT-1908 targeting fibrostenotic Crohn's Disease via oral PDE4 compound."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-032118","json":"https://secwatch.observer/filing/0001493152-23-032118.json","markdown":"https://secwatch.observer/filing/0001493152-23-032118.md","text":"https://secwatch.observer/filing/0001493152-23-032118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223032118/0001493152-23-032118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223032118/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:02:52.429175+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8eebcb86962d29c60770cfd8da2731ddb8d9dc2b","claim":"PALISADE BIO, INC. entered into Research Collaboration and License Agreement with Giiant Pharma Inc. valued at The Company is receiving an exclusive worldwide license to develop, manufacture, and commercialize s (effective 2023-09-01).","evidence_excerpt":"On September 1, 2023 (the “Effective Date”), Palisade Bio, Inc. (the “Company”) entered into a Research Collaboration and License Agreement (the “License Agreement”) with Giiant Pharma Inc. (“Giiant”) whereby the Company is receiving an exclusive (even as the Giiant and its affiliates), worldwide license (with the right to sublicense in multiple tiers) to develop, manufacture, and commercialize substantially all of the assets of Giiant, including: (i) the GT-2018 compound and (ii) the GT-1908 compound and the associated intellectual property around each of the foregoing.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223032118/0001493152-23-032118-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Giiant Pharma Inc."},{"label":"Value","value":"The Company is receiving an exclusive worldwide license to develop, manufacture, and commercialize s"},{"label":"Effective","value":"2023-09-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}